Anita Brikman: There Are Countless More Individuals Who Would Benefit from Access to Plasma-Derived Medicines
Anita Brikman, President and CEO of the Plasma Protein Therapeutics Association (PPTA), shared on LinkedIn:
”As International Plasma Awareness Week comes to a close, I’m grateful to all who supported the incredible efforts to recognize the lifesaving power of plasma and plasma donors. It was truly moving to see how Plasma Powers Possibility for so many around the globe.
But it is also clear that our mission doesn’t stop here. There are countless more individuals who would benefit from access to plasma-derived medicines, especially those in lower and middle income countries where the availability of treatment for rare diseases is limited at best.
The Plasma Protein Therapeutics Association (PPTA) efforts around awareness, advocacy, and access will continue on a daily basis. Because in reality, every week should be an awareness week filled with opportunities to reach out and educate. Pictured below are some of our awareness and activities from IPAW2025 including a powerful patient webinar, a Brussels panel on the Critical Medicines Act, a moving patient and donor meeting with GBS|CIDP Foundation International, and just one of the many patient testimonials we received over the last few days.
Next week, the momentum continues at the Plasma Protein Forum, where industry leaders, health care providers, and patient advocates will come together to advance innovation and address timely issues that impact the entire plasma community.
There’s still time to register, and I hope to see many of you there.
Visit the forum for more details on next week’s gathering.”
Stay updated with Hemostasis Today.
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 11, 2025, 09:00Muhammad Ali - Hematology In Pakistan: The Silent Revolution In Diagnosis And A Blueprint For Growth
-
Oct 11, 2025, 08:50Robert Zeiser: New Insights and Timeless Lessons in Transplantation
-
Oct 11, 2025, 08:39Mildred Lundgren: These 5 Proposals Are A Clear Road Map for The Future And We Support Them Wholeheartedly
-
Oct 11, 2025, 08:33RPTH Journal: Does Fasting Affect Anticoagulant Therapy? - The Effects Of Fasting During Ramadan
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 11, 2025, 18:47Endovascular Today: SYMPHONY-PE Trial and Advances in Pulmonary Embolism Treatment
-
Oct 11, 2025, 08:49Rodrigo Assar: We Are Pushing the Boundaries by Using Computational Approaches
-
Oct 11, 2025, 08:48Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
-
Oct 11, 2025, 08:34Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 11, 2025, 08:57Jeff June - Seeing The Invisible: How Spatial Biology Is Opening A New Chapter In Stroke Care
-
Oct 11, 2025, 08:11Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
-
Oct 11, 2025, 08:07Britta Diebel: This Has Been An Intense, Good Week, Although IPAW Actually Lasts All Year Long
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?